GeneGo Integrates MetaCore, MetaDrug With Spotfire's DecisionSuite for Drug Discovery

Jan 23, 2007

NEW YORK (GenomeWeb News) — GeneGo and Spotfire have integrated their software products for genomics, proteomics, and gene-expression analysis involved in drug development, GeneGo said today.

GeneGo’s MetaCore 4.2 is a biomarker-identification and -validation tool, and its MetaDrug platform is used to predict metabolism, toxicity, and the effects of small molecule compounds. Spotfire’s DecisionSuite, meantime, visualizes genomics data.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu